Extracellular glypican‐1 affects tumor progression and prognosis in esophageal cancer
Abstract Introduction Cells are covered with a glycan surface layer that is referred to as the glycocalyx (GCX). It has been reported that the formation of the GCX is promoted on cancer cells and is associated with tumor growth and metastasis. Heparan sulfate proteoglycan glypican‐1 (GPC1) is a core...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-09-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70212 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850238260897382400 |
|---|---|
| author | Rie Shibata Hirotaka Konishi Tomohiro Arita Yusuke Yamamoto Hayato Matsuda Taiga Yamamoto Takuma Ohashi Hiroki Shimizu Shuhei Komatsu Atsushi Shiozaki Takeshi Kubota Hitoshi Fujiwara Eigo Otsuji |
| author_facet | Rie Shibata Hirotaka Konishi Tomohiro Arita Yusuke Yamamoto Hayato Matsuda Taiga Yamamoto Takuma Ohashi Hiroki Shimizu Shuhei Komatsu Atsushi Shiozaki Takeshi Kubota Hitoshi Fujiwara Eigo Otsuji |
| author_sort | Rie Shibata |
| collection | DOAJ |
| description | Abstract Introduction Cells are covered with a glycan surface layer that is referred to as the glycocalyx (GCX). It has been reported that the formation of the GCX is promoted on cancer cells and is associated with tumor growth and metastasis. Heparan sulfate proteoglycan glypican‐1 (GPC1) is a core protein of the GCX that is overexpressed in esophageal squamous cell carcinoma (ESCC) and is involved in the development and progression of cancer cells. The purpose of the present study is to analyze the utility of GPC1 as a new biomarker ralated to glycocalyx that reflects therapeutic effect and prognosis of ESCC. Methods We measured the concentration of GPC1 protein in preoperative plasma from advanced esophageal cancer patients and examined its relationships with clinicopathological factors and therapeutic efficacy, and the effects of extracellular GPC1 were investigated. Results The following clinical factors were significantly correlated with the preoperative high GPC1 concentration: male, tumor size ≥30 mm, venous invasion, pT factor ≥2, pStage ≥3, residual tumor, and distant metastatic recurrence. Both overall and recurrence‐free survival were significantly worse in the high GPC1 group. Extracellular GPC1 protein concentration reflected intracellular GPC1 expression. Furthermore, we examined the effects of extracellular recombinant human (rh)GPC1 on ESCC cells, and found that extracellular rhGPC1 affects cell motility, including migration and invasion. Conclusions These results demonstrated the utility of extracellular GPC1 as a biomarker, which can be assayed from a less invasive blood sample‐based liquid biopsy. Extracellular GPC1 protein plays a role in both tumor cell motility and cancer progression. Thus, plasma GPC1 is a useful biomarker for esophageal cancer progression and may be a potential candidate of therapeutic target. |
| format | Article |
| id | doaj-art-ea82effada5a4f03af9274e5ce3e35ff |
| institution | OA Journals |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-ea82effada5a4f03af9274e5ce3e35ff2025-08-20T02:01:29ZengWileyCancer Medicine2045-76342024-09-011318n/an/a10.1002/cam4.70212Extracellular glypican‐1 affects tumor progression and prognosis in esophageal cancerRie Shibata0Hirotaka Konishi1Tomohiro Arita2Yusuke Yamamoto3Hayato Matsuda4Taiga Yamamoto5Takuma Ohashi6Hiroki Shimizu7Shuhei Komatsu8Atsushi Shiozaki9Takeshi Kubota10Hitoshi Fujiwara11Eigo Otsuji12Division of Digestive Surgery, Department of Surgery Kyoto Prefectural University of Medicine Kyoto JapanDivision of Digestive Surgery, Department of Surgery Kyoto Prefectural University of Medicine Kyoto JapanDivision of Digestive Surgery, Department of Surgery Kyoto Prefectural University of Medicine Kyoto JapanDivision of Digestive Surgery, Department of Surgery Kyoto Prefectural University of Medicine Kyoto JapanDivision of Digestive Surgery, Department of Surgery Kyoto Prefectural University of Medicine Kyoto JapanDivision of Digestive Surgery, Department of Surgery Kyoto Prefectural University of Medicine Kyoto JapanDivision of Digestive Surgery, Department of Surgery Kyoto Prefectural University of Medicine Kyoto JapanDivision of Digestive Surgery, Department of Surgery Kyoto Prefectural University of Medicine Kyoto JapanDivision of Digestive Surgery, Department of Surgery Kyoto Prefectural University of Medicine Kyoto JapanDivision of Digestive Surgery, Department of Surgery Kyoto Prefectural University of Medicine Kyoto JapanDivision of Digestive Surgery, Department of Surgery Kyoto Prefectural University of Medicine Kyoto JapanDivision of Digestive Surgery, Department of Surgery Kyoto Prefectural University of Medicine Kyoto JapanDivision of Digestive Surgery, Department of Surgery Kyoto Prefectural University of Medicine Kyoto JapanAbstract Introduction Cells are covered with a glycan surface layer that is referred to as the glycocalyx (GCX). It has been reported that the formation of the GCX is promoted on cancer cells and is associated with tumor growth and metastasis. Heparan sulfate proteoglycan glypican‐1 (GPC1) is a core protein of the GCX that is overexpressed in esophageal squamous cell carcinoma (ESCC) and is involved in the development and progression of cancer cells. The purpose of the present study is to analyze the utility of GPC1 as a new biomarker ralated to glycocalyx that reflects therapeutic effect and prognosis of ESCC. Methods We measured the concentration of GPC1 protein in preoperative plasma from advanced esophageal cancer patients and examined its relationships with clinicopathological factors and therapeutic efficacy, and the effects of extracellular GPC1 were investigated. Results The following clinical factors were significantly correlated with the preoperative high GPC1 concentration: male, tumor size ≥30 mm, venous invasion, pT factor ≥2, pStage ≥3, residual tumor, and distant metastatic recurrence. Both overall and recurrence‐free survival were significantly worse in the high GPC1 group. Extracellular GPC1 protein concentration reflected intracellular GPC1 expression. Furthermore, we examined the effects of extracellular recombinant human (rh)GPC1 on ESCC cells, and found that extracellular rhGPC1 affects cell motility, including migration and invasion. Conclusions These results demonstrated the utility of extracellular GPC1 as a biomarker, which can be assayed from a less invasive blood sample‐based liquid biopsy. Extracellular GPC1 protein plays a role in both tumor cell motility and cancer progression. Thus, plasma GPC1 is a useful biomarker for esophageal cancer progression and may be a potential candidate of therapeutic target.https://doi.org/10.1002/cam4.70212esophageal cancerglycocalyxglypican‐1GPC1liquid biopsy |
| spellingShingle | Rie Shibata Hirotaka Konishi Tomohiro Arita Yusuke Yamamoto Hayato Matsuda Taiga Yamamoto Takuma Ohashi Hiroki Shimizu Shuhei Komatsu Atsushi Shiozaki Takeshi Kubota Hitoshi Fujiwara Eigo Otsuji Extracellular glypican‐1 affects tumor progression and prognosis in esophageal cancer Cancer Medicine esophageal cancer glycocalyx glypican‐1 GPC1 liquid biopsy |
| title | Extracellular glypican‐1 affects tumor progression and prognosis in esophageal cancer |
| title_full | Extracellular glypican‐1 affects tumor progression and prognosis in esophageal cancer |
| title_fullStr | Extracellular glypican‐1 affects tumor progression and prognosis in esophageal cancer |
| title_full_unstemmed | Extracellular glypican‐1 affects tumor progression and prognosis in esophageal cancer |
| title_short | Extracellular glypican‐1 affects tumor progression and prognosis in esophageal cancer |
| title_sort | extracellular glypican 1 affects tumor progression and prognosis in esophageal cancer |
| topic | esophageal cancer glycocalyx glypican‐1 GPC1 liquid biopsy |
| url | https://doi.org/10.1002/cam4.70212 |
| work_keys_str_mv | AT rieshibata extracellularglypican1affectstumorprogressionandprognosisinesophagealcancer AT hirotakakonishi extracellularglypican1affectstumorprogressionandprognosisinesophagealcancer AT tomohiroarita extracellularglypican1affectstumorprogressionandprognosisinesophagealcancer AT yusukeyamamoto extracellularglypican1affectstumorprogressionandprognosisinesophagealcancer AT hayatomatsuda extracellularglypican1affectstumorprogressionandprognosisinesophagealcancer AT taigayamamoto extracellularglypican1affectstumorprogressionandprognosisinesophagealcancer AT takumaohashi extracellularglypican1affectstumorprogressionandprognosisinesophagealcancer AT hirokishimizu extracellularglypican1affectstumorprogressionandprognosisinesophagealcancer AT shuheikomatsu extracellularglypican1affectstumorprogressionandprognosisinesophagealcancer AT atsushishiozaki extracellularglypican1affectstumorprogressionandprognosisinesophagealcancer AT takeshikubota extracellularglypican1affectstumorprogressionandprognosisinesophagealcancer AT hitoshifujiwara extracellularglypican1affectstumorprogressionandprognosisinesophagealcancer AT eigootsuji extracellularglypican1affectstumorprogressionandprognosisinesophagealcancer |